Physician profile
Lien Tracy Dang
NPI 1225876345
$1,253.39
in general payments reported to CMS, 2019-2025
15 companies · $867 in 2025
The $867 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $386 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $381.55 | 2025 | |
| Cvrx, INC. | $175.14 | 2024-2025 | Barostim Neo System |
| Stryker Corporation | $169.85 | 2025 | Limflow System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $143.97 | 2024-2025 | Lifevest |
| Amgen INC. | $75.92 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $55.61 | 2024-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $42.68 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $39.17 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $36.46 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $35.15 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $21.13 | 2024 | Xarelto |
| Boston Scientific Corporation | $19.76 | 2024 | Varithena Administration Pack |
| Kiniksa Pharmaceuticals International, Plc | $16.91 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals Lp | $15.71 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.